Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emerald Health Therapeutics (EMH) appoints Nick Mosgrove as VP Sales & Marketing
  • Mosgrove was VP Sales & Marketing for TerrAscend Canada
  • Previously Mosgrove was Provincial Sales Manager in Ontario for Campari Canada, where he was responsible for $200M in retail sales value
  • Prior to this he held provincial sales manager roles in Ontario with Escalade Wines & Spirits, Select Wine & Spirits and Bacardi Canada
  • In these roles, he established and managed sales plans and led sales teams that resulted in improved key account satisfaction and sales growth while enhancing forecasting processes
  • Emerald Health Therapeutics, Inc. (EMH) is up 6.67 per cent and is trading at C$0.16 at 1:54 pm PT

Emerald Health Therapeutics, Inc. (EMH) has appointed Nick Mosgrove as VP Sales & Marketing.

Mosgrove has over 15 years of sales and marketing leadership experience in the Canadian alcohol beverage and cannabis sectors.

Most recently, Mosgrove was VP Sales & Marketing for TerrAscend Canada. In this role, he developed and implemented a commercial plan that resulted in over 1500 retail accounts across Canada, achieved a top 10 brand in year one, and doubled sales in 2020 from the first whole year of legal cannabis sales in Canada in 2019.

Previously Mosgrove was Provincial Sales Manager in Ontario for Campari Canada, where he was responsible for $200M in retail sales value. Prior to this he held provincial sales manager roles in Ontario with Escalade Wines & Spirits, Select Wine & Spirits and Bacardi Canada.

In these roles, he established and managed sales plans and led sales teams that resulted in improved key account satisfaction, sales growth while enhancing forecasting processes, supply chain effectiveness, and inventory efficiency.

“…our new Nano Shot product sold out in BC in six days and we have already received replenishment orders. Nano Shots will be available in Alberta this week and in Newfoundland and Labrador by month-end,” said Riaz Bandali, President & CEO of Emerald. 

“With our progress and commitment to introduce additional novel cannabis products, we are extending our investment in our sales and marketing efforts as well,” added Bandali.

Emerald looks to create new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products, with an emphasis on science-based innovation and product excellence.

Emerald Health Therapeutics, Inc. (EMH) is up 6.67 per cent and is trading at C$0.16 at 1:54 pm PT.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.